SINGAPORE, March 13 /PRNewswire-Asia/ -- Moleac Pte Ltd has been granted
the Emerging Company of the Year 2010 Award by BioSpectrum, the leading
integrated media platform for the Life Science Industry in the Asia Pacific.
This award recognizes Moleac's innovative business model; its contribution to
local community and business development; its ability to attract talents,
funds and peer admiration; and its potential to emerge as a major success
within the next three to five years.
Moleac took the ambitious bet to bring a first and innovative medicine to
market within four years with limited resources. To achieve this, Moleac has
identified in Traditional Medicines a number of natural ingredients and
preparations, carefully selected for their efficacy and absence of side
effects, which could address therapeutic gaps. In 2006, Moleac brought to
market NeuroAiD, the first treatment for post stroke recovery. Clinical trials
have shown that patients taking NeuroAiD within six months after a stroke have
2.4 more chance to achieve a fuller recovery. Currently, NeuroAiD is available
in multiple countries from the Asia Pacific to the Middle East region and on
the website http://www.neuroaid.com. NeuroAiD is the focus of CHIMES Society,
the largest-ever clinical trial on stroke recovery in Asia, which aims to
recruit 1,100 stroke patients.
Recent research results have confirmed that NeuroAiD supports the
neuroplasticity process during recovery after stroke through Brain-Derived
Neurotrophic Factor (BDNF) secretion. NeuroAiD has been shown to decrease
cognitive deficits, prevent death of threatened neuronal tissue and improve
functional outcomes by repairing and restoring neuronal circuits which have
been damaged after a stroke.
This recognition comes as another prestigious award, after being named by
Frost and Sullivan as the Entrepreneurial Company of the Year 2009. It is a
good appreciation of Moleac's early achievements and developments and
NeuroAiD's meaningful contribution to patients' heath in the pharmaceutical
industry.
Mr. David Picard, CEO of Moleac, together with nine other award winners,
received the BioSpectrum Asia Pacific Award 2010 at the award ceremony held on
the 12 of March 2010 in Singapore from Ministry of State Lee Yi Shyan. Other
recipients included Dr. Kallam Anji Reddy, Chairman, Dr Reddy's Labs, who
received the BioSpectrum Life Time Achievement Award.
David Picard said: "BioSpectrum is the most authoritative and influential
information healthcare industry in the Asia Pacific region. We are proud of
this recognition of our work and the difference we aim at making every day for
stroke survivors and their treating physicians."
Mr. Picard also added, "The past year, 2009, has been a positive one for
NeuroAiD development. NeuroAid reaches more and more stroke patients, thanks
to an increasing numbers of prescribing doctors. I am very pleased to see that
we make a meaningful contribution in the long recovery journey after stroke.
Our research and development team works tirelessly towards continuous
optimization of NeuroAiD formula. The latest breakthrough pharmacological data
paves the way for new indications of NeuroAiD in stroke prevention, cognitive
impairments and dementia. It is good news for patients who are in need of
treatments in this under-served therapeutic area. We would like to thank
everyone without whose support we would have never become the recipient of
this award: our academic partners, our investors, and of course my colleagues
who have made this project a success."
Moleac's achievements in 2009 include:
-- Launching NeuroAiD in new territories such as: Iran, Jordan, Thailand
and Pakistan. NeuroAiD is now listed in 10 countries and we are
currently reaching patients in over 25 countries through an internet
platform
-- Moleac receives the Award of Singapore Entrepreneurial Company of the
Year by Frost and Sullivan.
-- The establishment of a new office in Paris, which is located in
Biopark, a newly created research and scientific complex to enhance
scientific innovation in human health, as well as a subsidiary in
Brussels to support Moleac's European expansion;
-- Double volume of NeuroAiD sales compared to previous year
About Moleac
Moleac is a Singapore-based biopharmaceutical company that dedicates
itself in finding and developing new medicines for the unmet needs of patients
worldwide. http://www.moleac.net
About NeuroAiD
NeuroAiD is a stroke treatment to help stroke patients achieve faster and
better recovery. NeuroAiD is derived from natural components, carefully
selected for their efficacy and absence of side effects. It currently reaches
out to patients in over 25 countries. http://www.neuroaid.com
About BioSpectrum
BioSpectrum is a leading media platform in the Asia Pacific that provides
comprehensive coverage and useful insights in the exciting areas of
pharmaceuticals, biotechnology, medical devices, research & development and
policies. http://www.biospectrumasia.com
Contact details:
Kasia Kaminska
Telephone: +65 6478 9432
Email: kasia.kaminska@moleac.net
SOURCE Moleac
